1. Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients 
R.H.G.P. Arends, M.A. Karsdal, K.M. Verburg, C.R. West, A.C. Bay-Jensen, D.S. Keller 
Osteoarthritis and Cartilage 
Volume 25, Issue 6, Pages (June 2017)
DOI: /j.joca
Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions

2. Fig. 1
Baseline for patients with no NSAID use during screening and <90 days during treatment A) CART using a minimum split rule of 30 and B) corresponding ROC curve. Based on 2000 stratified bootstrap replicates with threshold set to 0.5, medians (95% CI) are: AUC =  (0.7753–0.8876), P < 0.0001; specificity =  (0.7078–0.8377); sensitivity =  (0.6522–0.8551); arrow denotes the predicted median specificity and the predicted median sensitivity.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions

3. Fig. 2
Baseline for patients with NSAID use during screening and <90 days during treatment A) CART using a minimum split rule of 30 and B) corresponding ROC curve. Based on 2000 stratified bootstrap replicates with threshold set to 0.5, medians (95% CI) are: AUC: (0.6881–0.8428), P <  ; specificity =  (0.4576–0.6356); sensitivity =  (0.6667–0.8958); arrow denotes the predicted median specificity and the predicted median sensitivity.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions

4. Fig. 3
Baseline for patients with NSAID use during screening and ≥90 days during treatment A) CART using a minimum split rule of 30 and B) corresponding ROC curve. Based on 2000 stratified bootstrap replicates with threshold set to 0.5, medians (95% CI) are: AUC =  (0.667–0.7965), P < 0.0001; thresholds = 0.5; specificity: ( ); sensitivity: (0.5385–0.7253); arrow denotes the predicted median specificity and the predicted median sensitivity.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions

5. Fig. 4
Box plots for the biomarker PINP at baseline, antecedent and coincident for cases and controls. NSAID user = NSAID was used during screening and ≥90 days during treatment; nonNSAID user = no NSAID use during screening and <90 days of NSAID use during treatment; scrNSAID user = NSAID use during screening and <90 days during treatment.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions

6. Fig. 5
Box plots for the biomarker ICTP at baseline, antecedent and coincident for cases and controls.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions